First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting

Micro-Abstract Renal cell carcinoma can be treated with angiogenesis inhibitors and mammalian target of rapamycin (mTOR) inhibitors. These agents have been studied in large clinical trials, but few studies of treatment outcomes in real-world settings have been performed. We found that the real-world outcomes of first-line pazopanib and second-line mTOR inhibitors (after pazopanib treatment) are generally consistent with those observed in clinical trials.